Joint Article on Hydrogen Peroxide Efficacy Published in Letters in Applied Microbiology
August 2, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wickham laboratories
Wickham Laboratories Ltd is pleased to announce the publication of a joint study with Bioquell on the efficacy of disinfection …
Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England
August 2, 2016Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer
Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …
Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III
August 2, 2016Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy
Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …
Pfizer expands gene therapy operations with acquisition of Bamboo Therapeutics
August 2, 2016Manufacturing and Production, Research and Development Pfizer, acquisition, bamboo therapeutics, gene therapy
Pfizer has announced that it has acquired gene therapy biotech Bamboo Therapeutics for an initial $150 million, with potential milestone …
Phase III success for Takeda in lymphoma drug
August 1, 2016Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma
Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …
FDA approves Shire’s haemophilia A treatment system
August 1, 2016Manufacturing and Production, Research and Development FDA, Shire, adynovate, baxject, haemophilia
Shire has announced that the Food and Drug Administration (FDA) has approved the baxject III reconstitution system for adynovate [antihemophilic …
The impact of Brexit on the pharmaceutical industry: some preliminary considerations
August 1, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing brexit
The outcome of the popular vote cast on 23 June 2016 will be remembered as the start of a new …
Sartorius doubles production capacity in UK with new facility
August 1, 2016Manufacturing and Production, Sales and Marketing Princess Anne, Sartorius, UK, expansion
Pharmaceutical and laboratory equipment provider Sartorius has expanded operations at its Stonehouse site in Gloucestershire with a new plant, doubling …
European Commission approves Zepatier for chronic hepatitis C infection
August 1, 2016Research and Development, Sales and Marketing
MSD, known as Merck in the US and Canada, has announced that the European Commission has approved Zepatier (elbasvir/grazoprevir) with …
Surprise for Seres as shares sent tumbling by Phase II failure
August 1, 2016Research and Development, Sales and Marketing FDA, clostrodium difficile, seres therapeutics
Seres Therapeutics has presented interim results from an ongoing Phase II trial which has sent company stock spiralling downward, as …
EMA accepts MMA for rheumatoid arthritis treatment Sarilumab
August 1, 2016Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …
GSK and Alphabet to create bioelectronics medicines in £540 million partnership
August 1, 2016Research and Development, Sales and Marketing Alphabet, GSK, Verily, bioelectronic medicine, galvani, google
GlaxoSmithKline and Verily Life Sciences, a division of Google’s parent company Alphabet, have announced a £540 million partnership that will …
FDA fast tracks Shire’s SHP626 nonalcoholic steatohepatitis drug
July 29, 2016Research and Development FDA, SHP626, Shire, liver fibrosis, nash, volixibat, volxibat
The Food and Drug Administration (FDA) has granted Fast Track designation to Shire’s SHP626 (volixibat) treatment for patients suffering from …
Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016
July 29, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo
Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …
China’s Fosun seals $1.3 billion deal for Gland Pharma
July 29, 2016Medical Communications, Sales and Marketing acquisition, fosun, gland, takeover
Fosun Pharmaceutical has agreed a deal to purchase an 86.1% stake of Gland Pharma, which will see the Chinese firm …
Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial
July 29, 2016Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis
Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …
Earnings drop at Sanofi as it looks for a quick Medivation resolution
July 29, 2016Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings
Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …
Roche urges reform of Cancer Drugs Fund as NICE takes control
July 29, 2016Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche
Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …
Ashfield provides clarity on the age old debate: ‘Syndicated’ or ‘Dedicated’ field sales?
July 28, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Ashfield is understandably well placed to offer a balanced viewpoint on field sales teams. With over 20 years of experience, …
Strong early data on haemophilia gene therapy boosts Biomarin
July 28, 2016Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a
Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
